{"transactions":[{"id":1017747,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":74218,"kind":"organization","name":"BridgeBio Pharma LLC","position":1,"cik":"0002076615","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":2,"cik":"0001743881","reported_name":"BridgeBio Pharma, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-16T17:54:33.000Z","date":"2025-10-10","kind":"other","planned":false,"acquired":true,"shares":784720,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Shares are held by BridgeBio Pharma LLC (\"BBIO LLC\"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. (\"BBIO\"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the \"BBIO Directors\"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"(Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":14589846,"source":{"system":"sec-edgar","filing":"0001193125-25-241634","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2076615/000119312525241634/ownership.xml","form_type":"4"}},{"id":2895563,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-26T21:05:09.000Z","date":"2021-01-26","kind":"purchase","acquired":true,"shares":14428836,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 26, 2021, pursuant to the Agreement and Plan of Merger, dated as of October 5, 2020 (the \"Merger Agreement\"), by and among BridgeBio Pharma, Inc. (\"BridgeBio\"), Eidos Therapeutics, Inc. (\"Eidos\"), Globe Merger Sub I, Inc. (\"Merger Sub I\") and Globe Merger Sub II, Inc. (\"Merger Sub II\"), Merger Sub I merged with and into Eidos (the \"Initial Merger\"), with Eidos surviving the Initial Merger, and thereafter Eidos merged with and into Merger Sub II (the \"Subsequent Merger\" and, together with the Initial Merger, the \"Mergers\"), with Merger Sub II surviving the Subsequent Merger as an indirect and wholly owned subsidiary of BridgeBio under the name \"Eidos Therapeutics, Inc.\" (the \"Surviving Corporation\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each share of common stock, par value $0.001 per share, of Eidos (\"Eidos Common Stock\") issued and outstanding immediately prior to the Effective Time (subject to certain exceptions) was converted into the right to receive, at the election of each stockholder of Eidos, (A) 1.85 shares of BridgeBio's common stock (\"BridgeBio Common Stock\"), par value $0.001 per share (the \"Stock Consideration\"), or (B) $73.26 in cash (the \"Cash Consideration\"). As of the Effective Time, all shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled, and all shares of Merger Sub I held by BridgeBio Pharma LLC immediately prior to the consummation of the Initial Merger were converted into shares of the Surviving Corporation in the Mergers. As a result of the Mergers, BridgeBio now owns all of the outstanding shares of common stock of the Surviving Corporation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 26, 2021, pursuant to the Agreement and Plan of Merger, dated as of October 5, 2020 (the \"Merger Agreement\"), by and among BridgeBio Pharma, Inc. (\"BridgeBio\"), Eidos Therapeutics, Inc. (\"Eidos\"), Globe Merger Sub I, Inc. (\"Merger Sub I\") and Globe Merger Sub II, Inc. (\"Merger Sub II\"), Merger Sub I merged with and into Eidos (the \"Initial Merger\"), with Eidos surviving the Initial Merger, and thereafter Eidos merged with and into Merger Sub II (the \"Subsequent Merger\" and, together with the Initial Merger, the \"Mergers\"), with Merger Sub II surviving the Subsequent Merger as an indirect and wholly owned subsidiary of BridgeBio under the name \"Eidos Therapeutics, Inc.\" (the \"Surviving Corporation\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each share of common stock, par value $0.001 per share, of Eidos (\"Eidos Common Stock\") issued and outstanding immediately prior to the Effective Time (subject to certain exceptions) was converted into the right to receive, at the election of each stockholder of Eidos, (A) 1.85 shares of BridgeBio's common stock (\"BridgeBio Common Stock\"), par value $0.001 per share (the \"Stock Consideration\"), or (B) $73.26 in cash (the \"Cash Consideration\"). As of the Effective Time, all shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled, and all shares of Merger Sub I held by BridgeBio Pharma LLC immediately prior to the consummation of the Initial Merger were converted into shares of the Surviving Corporation in the Mergers. As a result of the Mergers, BridgeBio now owns all of the outstanding shares of common stock of the Surviving Corporation."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Calculation of number of shares give effect to the consummation of the Initial Merger described herein, in which shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled and the 1,000 shares of Merger Sub I held by BridgeBio were converted into an aggregate of 1,000 shares of common stock of the Surviving Corporation."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000899243-21-003286","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321003286/doc4.xml","form_type":"4"}},{"id":3465955,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-07-09T01:26:00.000Z","date":"2019-07-03","kind":"purchase","acquired":true,"shares":882353,"price":29.9005,"value":26382795.8765,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares were purchased by BridgeBio Pharma, LLC, a wholly-owned subsidiary of the Reporting Person."}],"balance_after":24575501,"source":{"system":"sec-edgar","filing":"0000899243-19-019337","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319019337/doc4.xml","form_type":"4"}},{"id":3508994,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-29T23:13:32.000Z","date":"2019-05-24","kind":"purchase","acquired":true,"shares":1103848,"price":25.93,"value":28622778.64,"ownership":{"direct":true},"balance_after":23693148,"source":{"system":"sec-edgar","filing":"0000899243-19-015088","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319015088/doc4.xml","form_type":"4"}},{"id":3732305,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T23:14:48.000Z","date":"2018-12-10","kind":"purchase","acquired":true,"shares":2664,"price":13.96,"value":37189.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Due to a clerical error, the Form 4 filed on December 12, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the shares were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety.  All other information set forth in the December 12, 2018 Form 4 remains correct."},{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part,"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares purchased ranging from $13.86 to $14.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Due to a clerical error, the Form 4 filed on December 12, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the shares were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety.  All other information set forth in the December 12, 2018 Form 4 remains correct."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part,"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22589300,"source":{"system":"sec-edgar","filing":"0000899243-18-030928","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030928/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-12"}},{"id":3732304,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T23:14:48.000Z","date":"2018-12-10","kind":"purchase","acquired":true,"shares":37989,"price":13.29,"value":504873.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Due to a clerical error, the Form 4 filed on December 12, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the shares were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety.  All other information set forth in the December 12, 2018 Form 4 remains correct."},{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part,"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares purchased ranging from $12.85 to $13.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Due to a clerical error, the Form 4 filed on December 12, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the shares were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety.  All other information set forth in the December 12, 2018 Form 4 remains correct."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part,"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22586636,"source":{"system":"sec-edgar","filing":"0000899243-18-030928","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030928/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-12"}},{"id":3732342,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T23:13:58.000Z","date":"2018-12-07","kind":"purchase","acquired":true,"shares":4860,"price":14.36,"value":69789.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct."},{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares purchased ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22548647,"source":{"system":"sec-edgar","filing":"0000899243-18-030927","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030927/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-10"}},{"id":3732341,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T23:13:58.000Z","date":"2018-12-07","kind":"purchase","acquired":true,"shares":36314,"price":13.94,"value":506217.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct."},{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares purchased ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22543787,"source":{"system":"sec-edgar","filing":"0000899243-18-030927","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030927/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-10"}},{"id":3732340,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-13T23:13:58.000Z","date":"2018-12-06","kind":"purchase","acquired":true,"shares":38970,"price":13.34,"value":519859.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct."},{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares purchased ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of \"S\" instead of \"P\" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22507473,"source":{"system":"sec-edgar","filing":"0000899243-18-030927","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030927/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-10"}},{"id":3734171,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-12T22:44:20.000Z","date":"2018-12-10","kind":"sale","acquired":true,"shares":2664,"price":13.96,"value":37189.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $13.86 to $14.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22589300,"source":{"system":"sec-edgar","filing":"0000899243-18-030738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030738/doc4.xml","form_type":"4"}},{"id":3734170,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-12T22:44:20.000Z","date":"2018-12-10","kind":"sale","acquired":true,"shares":37989,"price":13.29,"value":504873.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $12.85 to $13.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22586636,"source":{"system":"sec-edgar","filing":"0000899243-18-030738","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030738/doc4.xml","form_type":"4"}},{"id":3737824,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-11T00:25:45.000Z","date":"2018-12-07","kind":"sale","acquired":true,"shares":4860,"price":14.36,"value":69789.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price of the shares sold ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22548647,"source":{"system":"sec-edgar","filing":"0000899243-18-030596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030596/doc4.xml","form_type":"4"}},{"id":3737823,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-11T00:25:45.000Z","date":"2018-12-07","kind":"sale","acquired":true,"shares":36314,"price":13.94,"value":506217.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22543787,"source":{"system":"sec-edgar","filing":"0000899243-18-030596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030596/doc4.xml","form_type":"4"}},{"id":3737822,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-11T00:25:45.000Z","date":"2018-12-06","kind":"sale","acquired":true,"shares":38970,"price":13.34,"value":519859.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22507473,"source":{"system":"sec-edgar","filing":"0000899243-18-030596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030596/doc4.xml","form_type":"4"}},{"id":3741657,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-07T01:48:00.000Z","date":"2018-12-05","kind":"purchase","acquired":true,"shares":1103848,"price":14.01,"value":15464910.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":22468503,"source":{"system":"sec-edgar","filing":"0000899243-18-030324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030324/doc4.xml","form_type":"4"}},{"id":3741656,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-12-07T01:48:00.000Z","date":"2018-12-03","kind":"purchase","acquired":true,"shares":1750000,"price":15.5,"value":27125000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities;"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All shares of the Issuer's Common Stock, par value $0.001 per share (the \"Common Stock\") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the \"IPO\"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock; (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities;"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from Footnote 1) or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO."}],"balance_after":21364655,"source":{"system":"sec-edgar","filing":"0000899243-18-030324","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318030324/doc4.xml","form_type":"4"}},{"id":3883243,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2018-06-26T20:30:49.000Z","date":"2018-06-22","kind":"exercise","acquired":false,"shares":12832123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15347219},"source":{"system":"sec-edgar","filing":"0000899243-18-018143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318018143/doc4.xml","form_type":"4"}},{"id":3883242,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-06-26T20:30:49.000Z","date":"2018-06-22","kind":"exercise","acquired":false,"shares":2909029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3479198},"source":{"system":"sec-edgar","filing":"0000899243-18-018143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318018143/doc4.xml","form_type":"4"}},{"id":3883241,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-06-26T20:30:49.000Z","date":"2018-06-22","kind":"other","acquired":true,"shares":332262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis."}],"balance_after":2909029,"derivative":{"underlying":"Common Stock","underlying_shares":397385},"source":{"system":"sec-edgar","filing":"0000899243-18-018143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318018143/doc4.xml","form_type":"4"}},{"id":3883240,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2018-06-26T20:30:49.000Z","date":"2018-06-22","kind":"other","acquired":false,"shares":332262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock."}],"balance_after":0,"derivative":{"exercise_price":10.8348,"underlying":"Series B Preferred Stock","underlying_shares":332262},"source":{"system":"sec-edgar","filing":"0000899243-18-018143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318018143/doc4.xml","form_type":"4"}},{"id":3883239,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T20:30:49.000Z","date":"2018-06-22","kind":"purchase","acquired":true,"shares":1000000,"price":17,"value":17000000.0,"ownership":{"direct":true},"balance_after":19614655,"source":{"system":"sec-edgar","filing":"0000899243-18-018143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318018143/doc4.xml","form_type":"4"}},{"id":3883238,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T20:30:49.000Z","date":"2018-06-22","kind":"tax_withholding","acquired":false,"shares":211762,"price":17,"value":3599954.0,"ownership":{"direct":true},"balance_after":18614655,"source":{"system":"sec-edgar","filing":"0000899243-18-018143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318018143/doc4.xml","form_type":"4"}},{"id":3883237,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO","position":1,"cik":"0001743881","reported_name":"BridgeBio Pharma LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T20:30:49.000Z","date":"2018-06-22","kind":"exercise","acquired":true,"shares":18826417,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18826417,"source":{"system":"sec-edgar","filing":"0000899243-18-018143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924318018143/doc4.xml","form_type":"4"}}]}